📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 5 fois dans les médias — pédagogie reconnue
Expérience confirmée
27 ans d'exercice en rhumatologie — recul clinique solide
27ans d'exercice (thèse 1999)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Métabolisme purique chez le pécher. Recherche d'enzymes marqueurs de potentialités de croissance des bourgeons : étude de l'adénine phosphoribosyltransferase et de l'adénosine nucleosidase
1999Direction : FRANCOIS LE FLOC'H
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
34
34 articles ont été cités au moins 34fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
4 683
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
234
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
74
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Bioprojet (France)
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study
2025ArticleSleep Medicine
Long-term efficacy and safety of pitolisant for residual sleepiness due to Obstructive Sleep Apnea
2024ArticleChest
Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial
2023ArticleThe Lancet Neurology
Seismic Monitoring of Permafrost in Svalbard, Arctic Norway
2021ArticleSeismological Research Letters
Alley Cropping Mitigates the Impacts of Climate Change on a Wheat Crop in a Mediterranean Environment: A Biophysical Model-Based Assessment
2021ArticleAgriculture
Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP
2021ArticleChest
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial
2020ArticleAmerican Journal of Respiratory and Critical Care Medicine
Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study
2019ArticleSleep
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Le Populaire du Centre · 24/02/2026
<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxQMFE0TU0xdzFSdlRqOEhTNXpMeTRQWnhVQjFTdGxDaXFjY21ZWTQ0d0k4RldXTzNYWWxFYmlGSVBiWkh1eUZ2RGZwRzQtV1FKQnlycW5TTWJGNGxtcmo4eF9WQlBTeGJ1U09QOUU3cmZ0dFVLUWVkVkF6UjhYRFFZd0JSQ2dQc1ZLSkdpN1ppTGkwU3ZaXzJuMGFFeUZrTDZveFA2aUdyX0c2dVJXWE5FSEU3VkJtbllraW
📰 La République du Centre · 09/11/2024
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOcEpyUk9PcnFKMm1vUmNmRnAyaU9SRi0wOWlaazVMV3FhTHRpWE9aUFBYbkJNQmRNT0NkVTA3M3lUT3Bhajl4OU5VMU53czZkWlNWaHpDU3pIUi1PSGcyRlNsM3NIMGNlZ2UxVWJ6MnZGQXNkU2lJSjROVDY5TUVJeXN2a1Y4dlM5UHMzUkVQSXJrdw?oc=5" target="_blank">Le projet présenté aux rivera
📰 Regards protestants · 11/08/2024
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNbmo2RmxVVWdCTXBzSWJZWHhvMTUtV2Y1RkhaeHozRmdCVlI0OW1EYmVmMGFobXFmNXhrZFQ0MlE4N1V4Z1EtektZZ2pXMDBVWFY0allILS1lbFpiY1R6SWIzZldxTy1uOThHRm53WUJTQWNuSG5sY0NxenU1eTB5bldxUzBCY1VndkJSLW96YVJpRDhPdC11OW1ldGtyMTN3WkpZV2h6ell6LTVkRWEycU9RZ1U4ZnpTM0
📰 Actu.fr · 30/04/2022
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPSmJZZnRUc2lZLVBpa2EzdGdxZkxYLUhIUjJFdW9CTjRQWkpNNVJRVjAwcmo5ajZxcTlZcENrdElvVVZQUVJLUE83UHc4cXlaYWQ1ZWcyUDhxaHF0Smg5dXVDV29RS1ZGRHJMZmE5TEhvTVdoZnkyN0FOU2gxLV9BdHc5QTNFZHlVbUx5N0FNYnBkWXprMjhYMHdsU3hsVFhiSHV5LUpXSTZBWVNZNmVQZHVxSTdZUQ?oc=
📰 Midi Libre · 17/07/2014
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNR2hPY3ppZzBVSF9QdEZTV0VHMnZvQ1Bfb184NkdLcU41RHVINkktUVFWYmpXWTMycUU3T2kzNzk3cnlORGstbHBEWjVqRU1QVlFzZUlqLW5rSTd2NzN6b2dwWEh1dVVVazNYb0lBTEdvWXZxNG83Tl95WUJQSEFXNmVZRmdWSTlGd3ZLNGptc1ZLMVo0cmxibjc5LXQzVGVReVpGR25VNFplY2RZYXMwWDMwZVk3dEZ4MW
The Lancet. Neurology · 2017
American journal of respiratory and critical care medicine · 2020
Abstract Rationale Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the treatment of daytime sleepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treatment. Methods In an international, multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was individually titrated at up to 20 mg/d over 12 weeks. The primary endpoint was the change in the Epworth Sleepiness Scale score. Key secondary endpoints were maintenance of wakefulness assessed on the basis of the Oxford Sleep Resistance test, safety, Clinical Global Impression of severity, patient’s global opinion, EuroQol quality-of-life questionnaire, and Pichot fatigue questionnaire. Measurements and Main Results A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea–hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 to pitolisant and 68 to placebo) and analyzed on an intention-to-treat basis. The Epworth Sleepiness Scale score was reduced more with pitolisant than with placebo (−2.8; 95% confidence interval, −4.0 to −1.5; P &lt; 0.001). Wake maintenance tests were not improved. The Pichot fatigue score was reduced with pitolisant. The overall impact of pitolisant was confirmed by both physicians’ and patients’ questionnaires. Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns. Conclusions Pitolisant significantly reduced self-reported daytime sleepiness and fatigue and improved patient-reported outcomes and physician disease severity assessment in sleepy patients with obstructive sleep apnea refusing or nonadherent to continuous positive airway pressure. Clinical trial registered with www.clinicaltrials.gov (NCT01072968) and EU Clinical Trials Register (EudraCT 2009-017251-94).
Sleep · 2019
AbstractStudy ObjectivesTo asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy.MethodsThis open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and Epworth Sleepiness Scale (ESS) score ≥12. After a titration period, patients were treated for up to 1 year with oral pitolisant once-a-day at up to 40 mg. Concomitant stimulants and anti-cataplectic agents were allowed. The primary endpoint was safety; secondary endpoints included ESS, cataplexy, and other diary parameters.ResultsPatients (n = 102, 75 with cataplexy) received pitolisant, for the first time in 73 of them. Sixty-eight patients (51 with cataplexy) completed the 12-month treatment. Common treatment-emergent adverse events were headache (11.8% of patients), insomnia (8.8%), weight gain (7.8%), anxiety (6.9%), depressive symptoms (4.9%), and nausea (4.9%). Seven patients had a serious adverse effect, unrelated to pitolisant except for a possibly related miscarriage. One-third of patients stopped pitolisant, mostly (19.6%) for insufficient benefit. ESS score decreased by 4.6 ± 0.6. Two-thirds of patients completing the treatment were responders (ESS ≤ 10 or ESS decrease ≥ 3), and one third had normalized ESS (≤10). Complete and partial cataplexy, hallucinations, sleep paralysis, and sleep attacks were reduced by 76%, 65%, 54%, 63%, and 27%, respectively. Pitolisant as monotherapy (43% of patients) was better tolerated and more efficacious on ESS than on add-on, but efficacy was maintained in this last case.ConclusionsLong-term safety and efficacy of pitolisant on daytime sleepiness, cataplexy, hallucinations, and sleep paralysis is confirmed.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Lancet. Neurology · 2023 · Randomized Controlled Trial
Dauvilliers Y, Lecendreux M, Lammers GJ, Franco P, et al.
Chest · 2021 · Journal Article
Pépin JL, Georgiev O, Tiholov R, Attali V, et al.
American journal of respiratory and critical care medicine · 2020 · Journal Article
Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, et al.
The Lancet. Neurology · 2017 · Journal Article
Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, et al.
Sleep medicine · 2025 · Journal Article
Plazzi G, Mayer G, Bodenschatz R, Bonanni E, et al.
Chest · 2024 · Journal Article
Pépin JL, Attali V, Caussé C, Verbraecken J, et al.
The Lancet. Neurology · 2023 · Randomized Controlled Trial
Dauvilliers Y, Lecendreux M, Lammers GJ, Franco P, et al.
Sleep medicine · 2025 · Journal Article
Plazzi G, Mayer G, Bodenschatz R, Bonanni E, et al.
American journal of respiratory and critical care medicine · 2020 · Journal Article
Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, et al.
Sleep · 2019 · Journal Article
Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, et al.
The Lancet. Neurology · 2023 · Randomized Controlled Trial
Dauvilliers Y, Lecendreux M, Lammers GJ, Franco P, et al.
The Lancet. Neurology · 2023 · Randomized Controlled Trial
Dauvilliers Y, Lecendreux M, Lammers GJ, Franco P, et al.
European journal of gastroenterology & hepatology · 2006 · Case Reports
Bachmeyer C, Barrier A, Frazier A, Fulgencio JP, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022 · Journal Article
Mutti C, Brunetti V, Figorilli M, Liguori C, et al.
Sleep medicine · 2025 · Journal Article
Plazzi G, Mayer G, Bodenschatz R, Bonanni E, et al.
Seismic interpretation of sill complexes in sedimentary basins: implications for the sub-sill imaging problem
This is a supplement to the paper "Seismic interpretation of Sill-Complexes in Sedimentary Basins: Implications for the Sub-Sill Imaging Problem" by "Christian Haug Eide, Nick Schofield, Isabelle Lecomte, Simon J. Buckle
Seismic interpretation of sill complexes in sedimentary basins: implications for the sub-sill imaging problem
This is a supplement to the paper "Seismic interpretation of Sill-Complexes in Sedimentary Basins: Implications for the Sub-Sill Imaging Problem" by "Christian Haug Eide, Nick Schofield, Isabelle Lecomte, Simon J. Buckle
Reservoir modelling strategies for intra-reservoir faulting
Conference presentation, presented at: Handling Fault Seals, Baffles, Barriers and Conduits.<br><br>Hosted by the Geological Society of London, 15-17 November 2017<br>Abstract:<br>Small-scale, intra-reservoir faulting ch
Analysing detection thresholds of lithological complexity and karst overprinting in outcrop-scale seismic models (SeisRox Pro modelling projects - supplementary data)
This dataset includes pre-loaded and integrated data sets used for seismic modelling based on geomodels created by interpretation of DOMs. The dataset includes: Five different SeisRox modelling projects of the Landnø
Analysing detection thresholds of lithological complexity and karst overprinting in outcrop-scale seismic models (SeisRox Pro modelling projects - supplementary data)
This dataset includes pre-loaded and integrated data sets used for seismic modelling based on geomodels created by interpretation of DOMs. The dataset includes: Five different SeisRox modelling projects of the Landnø
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
The Lancet. Neurology · 2017 · Journal Article
Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, et al.
✨ Profil synthétique
IA · 22/05/2026MME Isabelle LECOMTE est une rhumatologue avec un profil académique diversifié, comme en témoignent ses publications dans des domaines tels que la santé mentale, la gériatrie et la pédiatrie. Son h-index élevé de 34 reflète une production scientifique importante. Ses travaux de recherche couvrent également des aspects de la pharmacovigilance et des essais cliniques.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.